Laurus Labs (NSE: LAURUSLABS) – Bullish Or Bearish Analysis ,Price Target
Live Share Price & Chart
You can view the live NSE chart here:
TradingView Live Chart:
https://www.tradingview.com/symbols/NSE-LAURUSLABS/
NSE Quote:
https://www.nseindia.com/get-quotes/equity?symbol=LAURUSLABS
Laurus Labs Bullish Or Bearish = Bullish
Laurus Labs Price Target In 2030 = 8000 above
Company Overview
Laurus Labs is one of India’s leading pharmaceutical manufacturers specializing in:
- Active Pharmaceutical Ingredients (API)
- Contract Development & Manufacturing (CDMO)
- Generic Formulations
- Biotechnology
- Specialty Chemicals
The company exports to more than 80 countries and supplies major global pharmaceutical companies.
Option Traders (FNO Traders )
- One of the momentum Stock in pharma Sector
- For Option Traders Might Helpful the stock
- If Stock Fallen On market Fall Then Buy Call option in 15 min Support
- After Market Wake Laurus Surely going up Then Book The profits
- Because The pharma Sector also Going Good in Upcoming Days
Fundamental Analysis
| Particular | Details |
|---|---|
| Sector | Pharmaceuticals |
| Market Cap | ₹80,000+ Crore |
| Business Model | API + CDMO + Formulations |
| ROE | Improving |
| ROCE | Strong improvement |
| Debt | Low |
| Cash Flow | Positive |
| Promoter Holding | Stable |
| Export Revenue | Around 60%+ |
| Dividend | Low Yield |
Recent revenue and earnings have grown strongly, supported by higher CDMO demand and improved operating leverage.
Strengths
✅ Strong CDMO order pipeline
✅ Global customer base
✅ USFDA-approved manufacturing facilities
✅ Healthy balance sheet
✅ Expansion into peptides and biologics
✅ Consistent capacity expansion
Risks
- USFDA regulatory observations
- Currency fluctuations
- Pricing pressure in generic drugs
- High valuation after recent rally
- Pharma sector volatility
Growth Drivers
- CDMO business expansion
- Oncology APIs
- Biotechnology segment
- Peptide manufacturing
- Export growth
- Capacity expansion over the next two years
Management has announced significant capital expenditure focused on CDMO, peptides, fermentation and advanced therapies, which many analysts view as a long-term growth driver.
Financial Snapshot
| Metric | View |
|---|---|
| Revenue Growth | ⭐⭐⭐⭐⭐ |
| Profit Growth | ⭐⭐⭐⭐⭐ |
| Debt | ⭐⭐⭐⭐☆ |
| Cash Flow | ⭐⭐⭐⭐☆ |
| Margin Expansion | ⭐⭐⭐⭐⭐ |
| Long-Term Growth | ⭐⭐⭐⭐⭐ |
Technical View
Current Trend: Strong Bullish
Support Levels
- ₹1,350
- ₹1,250
- ₹1,150
Resistance Levels
- ₹1,500
- ₹1,650
- ₹1,800
A sustained move above ₹1,500 with strong volume could indicate further upside, while a break below ₹1,350 would weaken the short-term trend.
Price Target
Short Term (3–6 Months)
- Target 1: 1,900
- Target 2: 2500
Medium Term (12 Months)
- Base Case: 3500
- Bullish Case: 5,000
Overall View
Laurus Labs remains one of the stronger growth stories in the Indian pharmaceutical sector due to its expanding CDMO business, improving profitability, and ongoing investments in high-growth areas. However, after a sharp price rally, valuation has become richer, so staggered buying on market corrections may offer a better risk-reward profile than chasing the stock at new highs.
